Bristol Myers Squibb - WT2024-28 - POMALIDOMIDE (1mg, 2 mg, 3mg, 4mg) Capsules

GoodsAward procedure without prior publication of a call for competition

Awarded value£179,190published contract · exc. VAT

Awarded 23 Sept 2024no call for competition

Awarded to Bristol Myers Squibb

What is being bought

Published requirement description

Supply of POMALIDOMIDE (1mg, 2 mg, 3mg, 4mg) Capsules to meet clinical need in the Western Trust until 22/09/2025.

CPV: Pharmaceutical products

single lot · no lot value published

Lot #1Awarded

Delivery: Northern Ireland

From the official record

Procedure method: Award procedure without prior publication of a call for competition
Legal basis: CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
Procurement category: Goods
Notice status: Awarded without competition
Procurement threshold: Unspecified in notice
Regulatory regime: Standard
Commercial structure: Stand-alone contract (no framework)
Competition type: Direct award (no call for competition)
GPA / WTO covered: Yes (GPA)
Recurring procurement: Unspecified in notice
First published: 10 Oct 2024, 17:10 BST
Last source update: 10 Oct 2024, 17:10 BST
Authority reference: WT2024-28
FTS notice number: 2024/S 000-032701
Classification (CPV): Pharmaceutical products
Delivery area: Northern Ireland (UKN)
Official registry OCID: ocds-h6vhtk-04a7d0 Find a Tender

Why no open competition: The works, supplies or services can be provided only by a particular economic operator due to protection of exclusive rights, including intellectual property rights
Published justification: Regulation 32(2)(b)iii permits the award of a public contract by a negotiated procedure without prior publication where the works, supplies or services can only be supplied by a particular economic operator due to the protection of exclusive rights, including intellectual property rights. The absence of competition is not the result of an artificial narrowing down of the parameters of the procurement.
The Western Health and Social Care Trust requires the purchase of POMALIDOMIDE (1mg, 2 mg, 3mg, 4mg) Capsules which are subject to patent protection / Sole MA Holder and consequently no reasonable alternative of substitute exists.

Published awards, contracts and bid statistics, not a forecast

Awards 1

Awarded value £179,1901 contract exc. VAT

Bids received 1

Contracts signed 1latest 23 Sept 2024

Awarded to	Value	Date	Status
Bristol Myers Squibb	£179,190 †	—	Awarded

Contracts

Bristol Myers Squibb - WT2024-28 - POMALIDOMIDE (1mg, 2 mg, 3mg, 4mg) Capsules · Bristol Myers Squibb
Signed
23 Sept 2024
Value
£179,190
Status
active

Bid statistics published by the authority

Bids	SME	VCSE	Valid bid range
1bids	—	—	—

Contracting authorityCentral GovernmentBody governed by public lawHealth Londonderry, Northern IrelandContact name, email, phone

1 commercial party on the notice

BRISTOL-MYERS SQUIBB PHARMACEUTICALS LIMITEDAwarded supplierGB-COH: 02487574 NEW DENHAM, BUCKINGHAMSHIRE, South East

Official links; attachments are not copied

No document links were published on the notice.